TORONTO--(BUSINESS WIRE)--Medworxx Solutions Inc. ("Medworxx") (TSX VENTURE: MWX) today announced that TELUS Health will now offer customers the Medworxx Patient Flow Platform, enabling health care practitioners to better analyze and monitor patient health in an acute care environment. Comprised of Medworxx Clinical Criteria, Bed Management System, and Forms and Assessments, the platform is available as part of TELUS Health’s suite of technology solutions.
“Medworxx is excited to collaborate with TELUS Health and continue to expand Medworxx market penetration,” said Dan Matlow, President and CEO, Medworxx. “We look forward to the opportunity this partnership brings in building awareness and adoption of Medworxx technology in our key markets.”
Medworxx Patient Flow is a natural complement to Clinical Information Systems (CIS) such as TELUS’ OACIS. TELUS Health’s OACIS streamlines data through a single, intuitive source where clinicians can access, document and analyze a patient’s profile to identify and address their most urgent needs, ultimately increasing efficiency and productivity to deliver better healthcare.
“The addition of Medworxx to TELUS Health’s offering will bring additional value to our customers through our synergistic technologies and provide TELUS Health’s customers with additional capabilities to help drive proactive decision-making at the point of care,” said Kasra Moozar, vice-president, Healthcare Delivery Solutions, TELUS Health. “We are pleased to partner with Medworxx to bring their solutions to our customers as part of our expanding suite of acute care technology.”
About Medworxx
Medworxx delivers health information
solutions to over 350 hospitals internationally; including Canada,
United States and United Kingdom. Medworxx helps hospitals meet patient
flow challenges, and requirements in compliance and education. Medworxx
Clinical Criteria – flagship of Medworxx Patient Flow that includes
electronic bed board and independent assessment components – currently
serves over 35% of the acute care beds in Canada. Founded in 2004,
Medworxx is based in Toronto, ON, and publicly traded on the TSX Venture
Exchange: MWX.
Visit: http://www.medworxx.com/
About TELUS Health
TELUS Health is the leading information
and communication technology partner to Canada’s health system. With a
portfolio of telehomecare, electronic medical and health records,
consumer health, benefits management and pharmacy management solutions,
TELUS Health gives health authorities, providers, physicians, patients
and consumers the power to turn information into better health outcomes.
For more information about TELUS Health, please visit telushealth.com.
About TELUS
TELUS (TSX: T, NYSE: TU) is a leading national
telecommunications company in Canada, with $11.3 billion of annual
revenue and 13.3 million customer connections, including 7.8 million
wireless subscribers, 3.3 million wireline network access lines,
1.4 million Internet subscribers and 776,000 TELUS TV customers. Led
since 2000 by President and CEO, Darren Entwistle, TELUS provides a wide
range of communications products and services, including wireless, data,
Internet protocol (IP), voice, television, entertainment and video.
In support of our philosophy to give where we live, TELUS, our team members and retirees have contributed more than $300 million to charitable and not-for-profit organizations and volunteered 4.8 million hours of service to local communities since 2000. Fourteen TELUS Community Boards lead TELUS’ local philanthropic initiatives. TELUS was honoured to be named the most outstanding philanthropic corporation globally for 2010 by the Association of Fundraising Professionals, becoming the first Canadian company to receive this prestigious international recognition.
For more information about TELUS, please visit telus.com.
Disclaimer
The statements made in this press
release may contain forward-looking statements that may involve a number
of risks and uncertainties. Actual events or results could differ
materially from the company’s expectations and projections. The TSX
Venture Exchange has not reviewed this press release and neither
approved nor disapproved the information contained in this press release.
